CN1538853A - T细胞调节基因及其使用方法 - Google Patents

T细胞调节基因及其使用方法 Download PDF

Info

Publication number
CN1538853A
CN1538853A CNA028130154A CN02813015A CN1538853A CN 1538853 A CN1538853 A CN 1538853A CN A028130154 A CNA028130154 A CN A028130154A CN 02813015 A CN02813015 A CN 02813015A CN 1538853 A CN1538853 A CN 1538853A
Authority
CN
China
Prior art keywords
tim
thr
ser
leu
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028130154A
Other languages
English (en)
Chinese (zh)
Inventor
J��J������̫��
J·J·麦因太尔
�¿�³Ү��
R·H·德克鲁耶夫
÷
D·T·尤梅祖
G·J·弗里曼
V·库奇罗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of CN1538853A publication Critical patent/CN1538853A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CNA028130154A 2001-06-29 2002-07-01 T细胞调节基因及其使用方法 Pending CN1538853A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30234401P 2001-06-29 2001-06-29
US60/302,344 2001-06-29

Publications (1)

Publication Number Publication Date
CN1538853A true CN1538853A (zh) 2004-10-20

Family

ID=23167357

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028130154A Pending CN1538853A (zh) 2001-06-29 2002-07-01 T细胞调节基因及其使用方法

Country Status (11)

Country Link
US (2) US7553939B2 (enExample)
EP (1) EP1406653A4 (enExample)
JP (3) JP4572276B2 (enExample)
KR (1) KR20040014997A (enExample)
CN (1) CN1538853A (enExample)
CA (1) CA2452196A1 (enExample)
IL (1) IL159627A0 (enExample)
MX (1) MXPA04000034A (enExample)
NZ (1) NZ530451A (enExample)
WO (1) WO2003002722A2 (enExample)
ZA (1) ZA200400013B (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1778816B (zh) * 2004-11-22 2010-07-07 中国人民解放军第二军医大学 人细胞表面膜分子及用途
CN107602689A (zh) * 2012-12-20 2018-01-19 狮王株式会社 高血糖风险判定用标记肽及其用途
CN108037292A (zh) * 2017-11-29 2018-05-15 天津市湖滨盘古基因科学发展有限公司 一种人的磷脂酰丝氨酸受体突变蛋白及其应用
CN109790218A (zh) * 2016-08-26 2019-05-21 百济神州有限公司 抗tim-3抗体及其用途
CN110412263A (zh) * 2019-07-31 2019-11-05 中国农业科学院茶叶研究所 一种快速高效的茶树质体型谷氨酰胺合成酶基因定位方法
CN111499714A (zh) * 2017-04-10 2020-08-07 伊玛提克斯生物技术有限公司 用于癌症免疫治疗的肽及其肽组合物
CN114773486A (zh) * 2015-04-17 2022-07-22 高山免疫科学股份有限公司 具有可调的亲和力的免疫调节蛋白

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK285461B6 (sk) * 1996-05-24 2007-02-01 Biogen Idec Ma Inc. Izolovaný polypeptid KIM, modulátor tkanivovej regenerácie a nukleová kyselina, ktorá ho kóduje, spôsob prípravy polypeptidu a farmaceutická kompozícia obsahujúca polypeptid
CA2412734A1 (en) * 2000-06-16 2001-12-27 Biogen, Inc. Renal regulatory elements and methods of use thereof
DE60224275T2 (de) * 2001-06-01 2008-12-11 Biogen Idec Ma Inc., Cambridge Moleküle und verfahren zur inhibierung der freisetzung von kim-1
US8709412B2 (en) 2001-06-29 2014-04-29 The Board Of Trustees Of The Leland Stanford Junior University Modulation of TIM receptor activity in combination with cytoreductive therapy
US7838220B2 (en) 2001-06-29 2010-11-23 The Board Of Trustees Of The Leland Stanford Junior University T cell regulatory genes associated with immune disease
JP4572276B2 (ja) * 2001-06-29 2010-11-04 ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニヴァーシティ Ｔ細胞調節遺伝子およびその使用方法
EP4091631A1 (en) 2002-01-30 2022-11-23 The Brigham and Women's Hospital, Inc. A tim-3 binding molecule for use in the treatment of a disease
EP1576169B1 (en) * 2002-03-19 2016-08-10 Celldex Therapeutics, Inc. Therapeutic polypeptides and methods of use
AU2003299925B2 (en) * 2002-12-30 2011-10-27 Biogen Ma Inc. KIM-1 antagonists and use to modulate immune system
EP3000886A1 (en) * 2003-03-19 2016-03-30 Amgen Fremont Inc. Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof
AU2013242840B2 (en) * 2003-03-19 2017-01-19 Amgen Fremont Inc. Antibodies Against T Cell Immunoglobulin Domain and Mucin Domain 1 (TIM-1) Antigen and Uses Thereof
WO2005033144A2 (en) * 2003-10-03 2005-04-14 Brigham And Women's Hospital Tim-3 polypeptides
US20050197292A1 (en) * 2004-01-30 2005-09-08 Glennda Smithson Compositions and methods for treating T-cell mediated pathological conditions
TW200539890A (en) * 2004-03-12 2005-12-16 Brigham & Womens Hospital Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function
WO2005097211A2 (en) * 2004-03-24 2005-10-20 Telos Pharmaceuticals, Inc. Compositions as adjuvants to improve immune responses to vaccines and methods of use
EP2290070B1 (en) 2004-05-28 2015-03-25 Asuragen, Inc. Methods and compositions involving microRNA
ES2534302T3 (es) 2004-11-12 2015-04-21 Asuragen, Inc. Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
CN103751780A (zh) 2005-03-02 2014-04-30 比奥根艾迪克Ma公司 用于治疗th2介导的疾病的kim-1抗体
KR100746312B1 (ko) * 2005-03-14 2007-08-03 한국화학연구원 수용성 산화철 나노 입자 및 이의 제조방법
EP2115138A2 (en) * 2006-09-19 2009-11-11 Asuragen, Inc. Micrornas differentially expressed in pancreatic diseases and uses thereof
US8361714B2 (en) 2007-09-14 2013-01-29 Asuragen, Inc. Micrornas differentially expressed in cervical cancer and uses thereof
WO2009070805A2 (en) 2007-12-01 2009-06-04 Asuragen, Inc. Mir-124 regulated genes and pathways as targets for therapeutic intervention
WO2009111643A2 (en) * 2008-03-06 2009-09-11 Asuragen, Inc. Microrna markers for recurrence of colorectal cancer
EP2990487A1 (en) 2008-05-08 2016-03-02 Asuragen, INC. Compositions and methods related to mirna modulation of neovascularization or angiogenesis
EP2399934B1 (en) * 2009-02-20 2017-09-06 The University of Tokyo Novel monoclonal antibody, and use thereof
US9644241B2 (en) 2011-09-13 2017-05-09 Interpace Diagnostics, Llc Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
LT3116909T (lt) 2014-03-14 2020-02-10 Novartis Ag Antikūno molekulės prieš lag-3 ir jų panaudojimas
BR112017004826A2 (pt) 2014-09-13 2017-12-12 Novartis Ag terapias de combinação de inibidores de alk
TWI726920B (zh) 2015-10-14 2021-05-11 耶魯大學 基因體規模的ｔ細胞活性陣列、其製造方法、其用於辨識免疫調節因子的方法及其用途
CA3019199A1 (en) 2016-04-15 2017-10-19 Alpine Immune Sciences, Inc. Icos ligand variant immunomodulatory proteins and uses thereof
CN109476751B (zh) 2016-05-27 2024-04-19 艾吉纳斯公司 抗tim-3抗体及其使用方法
US20190248893A1 (en) 2016-07-14 2019-08-15 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
JP7730008B2 (ja) 2016-09-27 2025-08-27 セロ・セラピューティクス・ホールディングス・インコーポレイテッド キメラエンガルフメント受容体分子
WO2018086594A1 (en) * 2016-11-11 2018-05-17 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric tim-3
MX2020007266A (es) 2017-09-26 2020-09-07 Cero Therapeutics Inc Moleculas del receptor quimerico de engullido y metodos de uso.
EP3774865A1 (en) 2018-03-28 2021-02-17 Cero Therapeutics, Inc. Cellular immunotherapy compositions and uses thereof
US12291557B2 (en) 2018-03-28 2025-05-06 Cero Therapeutics Holdings, Inc. Chimeric TIM4 receptors and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6066322A (en) * 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
SK285461B6 (sk) * 1996-05-24 2007-02-01 Biogen Idec Ma Inc. Izolovaný polypeptid KIM, modulátor tkanivovej regenerácie a nukleová kyselina, ktorá ho kóduje, spôsob prípravy polypeptidu a farmaceutická kompozícia obsahujúca polypeptid
US5986059A (en) 1996-06-14 1999-11-16 Bayer Corporation T-cell selective interleukin-4 agonists
US7060458B1 (en) * 1997-08-14 2006-06-13 Wyeth Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
JP2002501738A (ja) * 1998-01-30 2002-01-22 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ６７個のヒト分泌タンパク質
ATE388224T1 (de) * 1998-03-27 2008-03-15 Prolume Ltd Luciferase, gfp fluoreszenzproteine, kodierende nukleinsaüre und ihre verwendung in der diagnose
WO2002081517A2 (en) 2001-01-19 2002-10-17 Curagen Corporation Novel polypeptides and nucleic acids encoded thereby
JP4572276B2 (ja) * 2001-06-29 2010-11-04 ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニヴァーシティ Ｔ細胞調節遺伝子およびその使用方法

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1778816B (zh) * 2004-11-22 2010-07-07 中国人民解放军第二军医大学 人细胞表面膜分子及用途
CN107602689A (zh) * 2012-12-20 2018-01-19 狮王株式会社 高血糖风险判定用标记肽及其用途
CN114773486A (zh) * 2015-04-17 2022-07-22 高山免疫科学股份有限公司 具有可调的亲和力的免疫调节蛋白
CN109790218A (zh) * 2016-08-26 2019-05-21 百济神州有限公司 抗tim-3抗体及其用途
CN109790218B (zh) * 2016-08-26 2023-03-03 百济神州有限公司 抗tim-3抗体及其用途
CN111499714A (zh) * 2017-04-10 2020-08-07 伊玛提克斯生物技术有限公司 用于癌症免疫治疗的肽及其肽组合物
CN108037292A (zh) * 2017-11-29 2018-05-15 天津市湖滨盘古基因科学发展有限公司 一种人的磷脂酰丝氨酸受体突变蛋白及其应用
CN110412263A (zh) * 2019-07-31 2019-11-05 中国农业科学院茶叶研究所 一种快速高效的茶树质体型谷氨酰胺合成酶基因定位方法
CN110412263B (zh) * 2019-07-31 2023-01-31 中国农业科学院茶叶研究所 一种快速高效的茶树质体型谷氨酰胺合成酶基因定位方法

Also Published As

Publication number Publication date
WO2003002722A3 (en) 2003-04-03
US20090252737A1 (en) 2009-10-08
MXPA04000034A (es) 2005-11-23
CA2452196A1 (en) 2003-01-09
JP4572276B2 (ja) 2010-11-04
JP2005500039A (ja) 2005-01-06
US20030124114A1 (en) 2003-07-03
JP2007000146A (ja) 2007-01-11
KR20040014997A (ko) 2004-02-18
WO2003002722A2 (en) 2003-01-09
US7553939B2 (en) 2009-06-30
EP1406653A2 (en) 2004-04-14
JP2010057492A (ja) 2010-03-18
NZ530451A (en) 2008-04-30
IL159627A0 (en) 2004-06-01
ZA200400013B (en) 2006-05-31
EP1406653A4 (en) 2005-05-04
JP4351233B2 (ja) 2009-10-28
WO2003002722A9 (en) 2004-04-15

Similar Documents

Publication Publication Date Title
CN1538853A (zh) T细胞调节基因及其使用方法
US9683049B2 (en) Modulation of TIM receptor activity in combination with cytoreductive therapy
CN1748143A (zh) 表达人cd20和/或cd16的转基因小鼠
US7838220B2 (en) T cell regulatory genes associated with immune disease
CN1665840A (zh) 含有免疫球蛋白结构域的细胞表面识别分子
CN1942581A (zh) 针对破骨细胞相关蛋白质的抗体
CN1413219A (zh) Rhd阴性基因座的分子结构
CN1254377A (zh) 哺乳动物chk1效应物细胞周期关卡蛋白激酶材料与方法
CN1279054C (zh) I型细胞因子受体tccr
CN1630664A (zh) 胱冬酶－8结合蛋白及其制备和使用
CN1795205A (zh) Spex组合物和使用方法
CN1809589A (zh) Gitr配体和gitr配体相关分子和抗体及其应用
CN1355845A (zh) PrP样基因
CN1152960C (zh) Icam-4的材料和方法
CN1865440A (zh) 肥厚型心肌病致病基因的新突变及其用途
CN1556814A (zh) 含有非功能性Kvβ1.1亚基N末端的敲入转基因哺乳动物
HK1069996A (en) T cell regulatory genes and methods of use thereof
CN101039956A (zh) 细胞表面糖蛋白
CN1399644A (zh) 新的人g蛋白偶联受体
US6803184B1 (en) MPR-related ABC transporter encoding nucleic acids and methods of use thereof
CN1194989C (zh) 具有抑制癌细胞生长功能的新的人蛋白及其编码序列
CN1169833C (zh) 具有抑癌功能的新的人蛋白及其编码序列
AU2002318462A1 (en) T cell regulatory genes and methods of use thereof
CN1746187A (zh) 心房颤动致病基因及其用途
CN1510139A (zh) 人类心房颤动致病基因和编码蛋白及其用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CI01 Publication of corrected invention patent application

Correction item: Applicant co applicant

Correct: The Dana Farber Cancer Institute of Limited by Share Ltd|Massachusetts Eye & Ear Infirmary

False: Missing open 2,3 co applicant

Number: 42

Volume: 20

CI02 Correction of invention patent application

Correction item: Applicant co applicant

Correct: The Dana Farber Cancer Institute of Limited by Share Ltd|Massachusetts Eye & Ear Infirmary

False: Missing open 2,3 co applicant

Number: 42

Page: The title page

Volume: 20

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT CO-APPLICANT; FROM: NON-PUBLICITY NO. 2,3 CO-APPLICANT TO: DANA FARBER CANCER INSTITUTE CO., LTD. BRIGHAM AND WOMEN S HOSPITAL CO., LTD.

ERR Gazette correction

Free format text: CORRECT: APPLICANT CO-APPLICANT; FROM: NON-PUBLICITY NO. 2,3 CO-APPLICANT TO: DANA - FARBER CANCER INSTITUTE CO., LTD. BRIGHAM AND WOMEN S HOSPITAL CO., LTD.

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1069996

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1069996

Country of ref document: HK